Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1832P - Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Breast Cancer

Presenters

Alejandro Olivares Hernandez

Citation

Annals of Oncology (2021) 32 (suppl_5): S1237-S1256. 10.1016/annonc/annonc701

Authors

A. Olivares Hernandez1, R.A. Escala Cornejo2, I. Toribio García3, L. Figuero Pérez4, R. Vidal Tocino5, J.P. Miramontes González6, G. Martín García4, R. Seijas Tamayo4, J.J. Cruz-Hernández7, C.A. Rodriguez Sanchez8

Author affiliations

  • 1 Medical Oncology Dept, IBSAL - Instituto de Investigación Biomédica de Salamanca, 37007 - Salamanca/ES
  • 2 Medical Oncology Department, Complejo Asistencial de Avila - Hospital Nuestra Senora de Sonsoles Urgencias, 05071 - Ávila/ES
  • 3 Cardiology, University Hospital of León, 24071 - León/ES
  • 4 Medical Oncology, University Hospital of Salamanca, 37007 - Salamanca/ES
  • 5 Medical Oncology Dept., IBSAL - Instituto de Investigación Biomédica de Salamanca, 37007 - Salamanca/ES
  • 6 Internal Medicine, University Hospital Rio Hortega, 47012 - Valladolid/ES
  • 7 Medical Oncology, Hospital Clinico Universitario de Salamanca, Salamanca/ES
  • 8 Medical Oncology, IBSAL - Instituto de Investigación Biomédica de Salamanca, 37007 - Salamanca/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1832P

Background

Approximately 15–20% of breast cancers (BC) overexpress the HER2 receptor (HER2+). The introduction of anti-HER2 therapies to the treatment of BC HER2+ has brought about a revolution in terms of survival and quality of life. However, some of these treatments have also led to an increase of cardiotoxicity at expense of decrease the left ventricular function (LVEF). Meanwhile, pertuzumab (PER) has not been shown to increase the risk of cardiac events. The aim of this study is to evaluate the existence of an increase in cardiotoxicity associated with PER treatments in BC HER2+ via a systematic review.

Methods

A systematic review was carried out according to PRISMA criteria based on clinical trials in BC HER2+ in all stages that included first-line PER treatment in either arm. The clinical trials included studies conducted between 1 January 2005 and 31 December 2020. The flow diagram included 459 articles, of which only 25 were ultimately selected. The statistical analysis was expressed in terms of the number of cardiac events, LVEF and deaths of cardiac origin. Statistical analysis was performed with SPSSv25.

Results

Of the 25 clinical trials evaluated, 10 addressed metastatic stages of BC, 14 focussed on localised BC and one BC in all stages. The total number of patients (pts) evaluated was 11,678, of which 7,768 (66,52%) belonged to PER-receiving groups and 3,910 (33,48%) were members of control groups. The numbers of cardiac events were 176 (2,31%) in the PER groups and 48 (1,23%) in groups without PER. LVEF was observed more frequently in groups with PER (179 events, 2,3%), compared to groups without PER (55 events, 1,41%), with the differences observed in pts with PER in localised, versus metastatic, stages of BC. The number of cardiac deaths was 12 (0,15%) among those given PER and 2 (0,05%) among without PER.

Conclusions

Despite the limitation of having no data on clinical trials directed toward the study of cardiotoxicity with PER, our study showed a higher tendency for BC HER2+ treatments with PER to present greater cardiotoxicity. Clinical trials in this field evaluating the true effect of these treatments on cardiac toxicity will be necessary to demonstrate our conclusions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.